Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer

Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined. We investigated the usefulness of systemic immunity markers associated with lymphocytes as predictive...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamoto, Shogo, Ikeda, Masahiko, Kubo, Shinichiro, Yamamoto, Mari, Yamashita, Tetsumasa, Notsu, Akifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973794/
https://www.ncbi.nlm.nih.gov/pubmed/33737682
http://dx.doi.org/10.1038/s41598-021-85948-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973794/
https://www.ncbi.nlm.nih.gov/pubmed/33737682
http://dx.doi.org/10.1038/s41598-021-85948-2

Ejemplares similares